Nikunj dalmia in conversation with Saurabh Mukherjee on @ETNOWlive
@HDFCLIFE - brought big data to their life insurance business
More questionnaire compared to other insurance players
More rigorous health checkups
Better underwriting & embedded value due to big data use
Another player using big data @BajajFinCorp - superior ROE compared to other NBFCs
Move to complete digitization helping IT firms @TCS reorients itself according to need of its fortune 500 clients ,moved from infrastructure software to application development to big data,cloud
@TCS ability to retrain lakhs of employees as per need is a big advantage
Next 3 months economic outlook to remain upbeat as Indis opens up
Small town real estate mkt is picking pace
Strong commentary from @HomeLoansByHDFC guided to strong recovery
Post lockdown pickup
Post lockdown pickup to demand pickup will give the next legup to BFSI players
Recovery strong demand picking up,even 2nd rung nbfc have access to funds due to strong liquidity
Cost of borrowing dropped 1.5% for 2nd rung lenders @PiramalGroup@DCBBank@IDFCFIRSTBank
@reliancegroup unparalleled in India in raising capital,execution of projects,building refineries in 80s to rolling out telecom now,but till return on capital exceeds cost of capital wont look at as a investment candidate
Going ahead look at auto,pharma,chemical,frontline nbfcs
Real estate demand picking up,home loans at 7%,tine to look at building Material companies(tiles,plywood,sanitaryware)
Hold @asianpaints, pidilite,astral poly but looking at other players
1991 moment for Agriculture
Better pricing power for farmers
Structural reforms in transport & logistics sector to ramp up
India to be the pharma capital of the world
Underownwrship of equities in India #Nifty#sensex#StockMarket
Percentage of corporate profits to GDP low in India
Api & generic companies to have both earnings & PE expansion
India focused pharma companies to have earnings but not PE expansion
Current pharma rally may last longer than previous rally #Nifty#traders#stocks#markets
Electric vehicle adaptation in India will be faster than anticipated
Climate change to drive consumer behavior
Recovery from #COVID19 faster than expected
Oppurtunity in Infra,Hotels sector
Value stocks @ITCCorpCom@TheOfficialSBI to gain in 2nd phase of bull mkt @ETNOWlive
Niraparib,orally active small molecule PARP inhibitor developed by Tesaro to Rx ovarian cancer, granted fast track designtn by USFDA in 2016
Apr'20 USFDA approved Zejula (niraparib) as monotherapy maintenance Rx for ovarian,fallopian tube,peritoneal cancer @GSK #dishmanpharma
Dishman Carbogen makes the API for the drug, has been supplying APIs to GSK from 2017
The approval will help Niraparib grow multifold,big positive for Dishman’s CRAMS business.
Niraparib API revenues for Dishman could grow twofold next 2 yrs #dishmancarbogenamcis#DCAL#niraparib
Zejula is currently approved as a maintenance therapy for adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer and whose tumors have completely or partially responded to platinum-based chemotherapy treatments
Zejula sales $295 million 2019 #dcal
4)Drizalma Sprinkle - Oct'19(duloxetine delayed release capsules) in US for oral use, serotonin & norepinephrine reuptake inhibitor for patients with neuropsychiatric & pain disorders in patients who have difficulty swallowing
Cipla Mkt share in Fluticasone propionate salmeterol pMDI is 20% in EU
#2 in sale of inhalers globally
Respiratory 22% share in total revenues
Foracort #10 among 4 @Cipla_Global brands that featured in top 50 brands in India
46% in MDIs & 65% in FPSM pMDI Mkt share in S Africa
Cipla in India 2020
$1bn orgnizatn,40% of revenue
Leadership in respiratory,urology,anti-virals
Launched foracort syncobreathe
Acquired brand & trademark for Vysov&Vysov M
Deal for Omalizumab(Allergic Asthma)with Reliance lifesciences
Stempeucel used in DM
Acq 4nutraceuticals
Navin fluorine
Traction in life & crop science business
Speciality chemicals & CRAMS(Dewas plant with cGMP) accounted for 64% sales in q1fy21
Company AR FY20,25% drugs approved by USFDA in fy19 contained fluorine molecules
Traditional inorganic fluoride & refrigerant business impacted due to slowdown in steel,glass industry due to COVID
$410mn 7 year contract starting q4fy22 for supply of high performance product in fluorochemical space,longterm visibility,capex $61.5mn thru debt,internal accruals
EV/EBIDTA of 29.74 it's more richly valued compared to Aarti,SRF
Fluorospar 60% raw material cost for navin,main producer China,company has dependance of 20%
Shift of businesses from China will aid Navin
Covid vaccine
Serum's Adar Poonawala expects to produce 4-5 mn doses/month initially,ramping up to 350-400 mn/yr @pfizer,@moderna_tx,@AstraZeneca all are in a race
But another ?
Which company supplies the vials,tubes to @SerumInstIndia required for storage/transport of vaccine?
SCHOTT KAISHA 50:50 JV between SCHOTT, the German specialty glass maker & Indian firm KAISHA,converts tubular glass into vials,ampoules, syringes,with a total capacity of 3 bn units @moneycontrolcom
Indian companies involved in vaccine research
Bharat Biotech
Panacea Biotec
Zydus Cadila Biological E
Indian Immunologicals
Trials for Bharat biotech started at AIIMS,New delhi
KEM Hosp Mumbai to start trials for Phase2,3 Astra vaccine #COVID19#coronavirus